IVERIC bio, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-12-29: Form 8-K; Period of report 2014-12-22; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2014-12-22: Form 8-K; Period of report 2014-12-16; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2014-11-13: Form 8-K; Period of report 2014-11-13; Description 2.01 Completion of Acquisition or Disposition of Assets; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; Details 2.01.
- 2014-11-12: Form 8-K; Period of report 2014-11-11; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-12-29 | 8-K | 2014-12-22 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a14-26842_18k.htm |
| 2014-12-22 | 8-K | 2014-12-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 16, 2014, the board of directors (the “Board”) of Ophthotech Corporation (the “Company”), following approval and recommendation from the compensation committee of the Board, approved new compensation arrangements for David R. Guyer, M.D., Chief Executive Officer, Samir C. Patel, M.D., President, and Michael Atieh, Chief Financial Officer, as described below. | a14-26629_18k.htm |
| 2014-11-13 | 8-K | 2014-11-13 | 2.01 Completion of Acquisition or Disposition of Assets; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement | 2.01 On November 13, 2014, Ophthotech Corporation (the “Company”) closed the third tranche of royalty financing pursuant to its royalty purchase and sale agreement with Novo A/S, dated May 23, 2013, as amended (the “Royalty Agreement”). 2.04 The disclosures set forth under Item 2.01 of this Current Report on Form 8-K are hereby incorporated by reference into this Item 2.04. | a14-24240_28k.htm |
| 2014-11-12 | 8-K | 2014-11-11 | 2.02 Results of Operations and Financial Condition | 2.02 On November 11, 2014, Ophthotech Corporation announced its financial results for the quarter ended September 30, 2014. | a14-24240_18k.htm |
| 2014-09-25 | 8-K | 2014-09-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 20, 2014, Bruce A. Peacock notified the Company of his resignation from his position as Chief Financial and Business Officer of Ophthotech Corporation (the “Company”), effective September 30, 2014. | a14-21483_18k.htm |
| 2014-09-22 | 8-K | 2014-09-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 17, 2014, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Ophthotech Corporation (the “Company”) approved a special cash bonus for Bruce Peacock, the Company’s Chief Financial and Business Officer, in the amount of $100,000. | a14-21282_18k.htm |
| 2014-08-06 | 8-K | 2014-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2014, Ophthotech Corporation announced its financial results for the quarter ended June 30, 2014. | a14-18464_18k.htm |
| 2014-05-23 | 8-K | 2014-05-19 | 1.01 Entry into a Material Definitive Agreement; 5.07 Submission of Matters to a Vote of Security Holders | 1.01 Entry into a Material Definitive Agreement. 5.07 Ophthotech held its Annual Meeting of Stockholders on May 21, 2014. | a14-13457_18k.htm |
| 2014-05-19 | 8-K | 2014-05-19 | 7.01 Regulation FD Disclosure | 7.01 On May 19, 2014, Ophthotech Corporation (the “Company”) entered into a licensing and commercialization agreement (the “Licensing and Commercialization Agreement”) with Novartis Pharma AG. | a14-13096_18k.htm |
| 2014-05-13 | 8-K | 2014-05-13 | 2.02 Results of Operations and Financial Condition | 2.02 On May 13, 2014, Ophthotech Corporation announced its financial results for the quarter ended March 31, 2014. | a14-12734_18k.htm |
| 2014-05-08 | 8-K | 2014-05-02 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a14-12364_18k.htm |
| 2014-02-27 | 8-K | 2014-02-27 | 2.02 Results of Operations and Financial Condition | 2.02 On February 27, 2014, Ophthotech Corporation announced its financial results for the quarter and year ended December 31, 2013. | a14-6887_18k.htm |
| 2014-01-29 | 8-K | 2014-01-29 | 2.01 Completion of Acquisition or Disposition of Assets; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement | 2.01 The first tranche of the royalty financing, in which Novo A/S purchased a low single-digit royalty interest and paid the Company $41,666,666, closed concurrently with the Company’s entry into the Royalty Agreement. 2.04 The disclosures set forth under Item 2.01 of this Current Report on Form 8-K are hereby incorporated by reference into this Item 2.04. | a14-3645_48k.htm |
| 2014-01-10 | 8-K | 2014-01-07 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a14-3330_18k.htm |